| Non-Small Cell Lung Carcinoma
Xalkori vs Lorbrena
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Xalkori vs Lorbrena with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLorbrena has a higher rate of injection site reactions vs Xalkori based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lorbrena but not Xalkori, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xalkori
Lorbrena
At A Glance
Oral
Twice daily
ALK/ROS1 inhibitor
Oral
Daily
ALK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Ki-1+ Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma Adults: 250 mg orally twice daily until disease progression or unacceptable toxicity.
Ki-1+ Anaplastic Large Cell Lymphoma Pediatric patients 1 year of age and older and young adults: 280 mg/m2 orally twice daily (BSA-based dosing) until disease progression or unacceptable toxicity.
Inflammatory Myofibroblastic Tumor Adults: 250 mg orally twice daily; pediatric patients 1 year of age and older: 280 mg/m2 orally twice daily (BSA-based dosing), until disease progression or unacceptable toxicity.
Non-Small Cell Lung Carcinoma 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Contraindications
—
- Concomitant use of strong CYP3A inducers, due to the potential for serious hepatotoxicity
Adverse Reactions
Most common (>=25%) Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, severe visual loss, gastrointestinal toxicity (in pediatric/young adult ALCL or pediatric IMT patients).
Postmarketing Increased blood creatine phosphokinase.
Most common (>=20%) Edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, cough
Serious Pneumonia, dyspnea, respiratory failure, cognitive effects, pyrexia
Pharmacology
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, ROS1, c-Met, and RON; it blocks ALK fusion protein-driven oncogenic signaling, inhibiting tumor cell proliferation and survival.
Lorlatinib is a kinase inhibitor with activity against ALK and ROS1, as well as multiple mutant forms of ALK including resistance mutations detected at progression on prior ALK inhibitors; antitumor activity is dose-dependent and correlates with inhibition of ALK phosphorylation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xalkori
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Lorbrena
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Xalkori
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Lorbrena
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Xalkori
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Lorbrena
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XalkoriView full Xalkori profile
LorbrenaView full Lorbrena profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.